Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04379713 · ClinicalTrials.gov registry record · Phase 3
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,511
- Enrollment target
NCT04379713 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,511 participants.
The verdict
NCT04379713, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,511 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.
Interventions
- BIOLOGICAL 20-valent pneumococcal conjugate vaccine
- BIOLOGICAL 13-valent pneumococcal conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,511 participants |
| Start Date | 2020-05-21 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04379713
The ClinicalTrials.gov registry entry for NCT04379713 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,511 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 20-valent pneumococcal conjugate vaccine is the first listed.
NCT04379713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04379713 about?
NCT04379713 is a clinical study titled "20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants". This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.
What is the current status of trial NCT04379713?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,511 participants. The study started on 2020-05-21. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT04379713?
The interventions under investigation include: 20-valent pneumococcal conjugate vaccine (BIOLOGICAL), 13-valent pneumococcal conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04379713?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.